Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > U-M Nanotechnology Institute collaborates in $6 million vaccine program

Abstract:
U-M scientists tapped to help NanoBio Corporation develop Respiratory Syncytial Virus (RSV) intranasal vaccine

U-M Nanotechnology Institute collaborates in $6 million vaccine program

Ann Arbor, MI | Posted on December 3rd, 2010

The University of Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) will be collaborating with a U-M spinout company to develop a safe and effective Respiratory Syncytial Virus (RSV) intranasal vaccine.

Approximately one-third of a nearly $6 million grant awarded to the Ann Arbor-based NanoBio Corporation by the Bill & Melinda Gates Foundation will be subcontracted to MNIMBS in exchange for a two-year commitment to the project to help characterize the mechanism of action and in vivo immunogenicity of a series of nanoemulsion adjuvants and nanoemulsion-RSV vaccines.

Respiratory syncytial virus (RSV) is highly contagious and causes infection of the lungs and breathing passages. While symptoms are mild in adults, it is a major cause of respiratory illness in young children and can, in rare cases, cause death in infants, especially in developing countries. Children may develop chronic pulmonary disease and/or asthma that persists throughout adult life, making them susceptible to re-infection as adults. Currently, there are no approved vaccines for RSV.

"While originally developed as microbicidal agents at the MNIMBS, studies fortuitously demonstrated that nanoemulsions are a promising new type of adjuvant for nasopharyngeal vaccines. A needle-free, intranasally administered nanoemulsion-based RSV vaccine would be a great advance in the effort to prevent RSV infection," says James R. Baker, Jr., M.D., director of the MNIMBS and Ruth Dow Doan Professor of Internal Medicine at U-M. He also is founder and CEO of NanoBio.

MNIMBS invented the vaccine technology, and this technology was then transferred to NanoBio Corp. who named it NanoStat.™ The company's lead vaccine candidate, NB-1008, is a seasonal influenza vaccine administered via a nasal dropper. In a recently completed Phase 1 clinical study, NB-1008 was safe, well tolerated and elicited both mucosal and systemic immune responses following a single intranasal vaccination in a study of 199 healthy adults.

Other intranasal vaccines under development in animals by the MNIMBS and NanoBio Corp. include pandemic influenza, hepatitis B, HIV, pneumococcal, anthrax and smallpox. This platform technology has demonstrated numerous advantages over traditional vaccines, including the ability to generate robust mucosal and systemic immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles and refrigeration.

####

About University of Michigan Nanotechnology Institute for Medicine and Biological Sciences
The Michigan Nanotechnology Institute for Medicine and Biological Sciences is a true multidisciplinary team of chemists, physicists, engineers, toxicologists, physicians, biologists, pharmacists, and (bio)informatics specialists collaborating on nanoscience in biology and medicine. The MNIMBS first developed the nanoemulsion-based NanoStat™ technology that is further commercialized by NanoBio Corp.

About NanoBio
NanoBio Corporation, a University of Michigan spinoff, is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are nanoemulsion based treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Disclosures: Baker holds an equity interest in the NanoBio Corporation.

For more information, please click here

Copyright © University of Michigan

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Academic/Education

Luleå University of Technology is using the Deben CT5000TEC stage to perform x-ray microtomography experiments with the ZEISS Xradia 510 Versa to understand deformation and strain inside inhomogeneous materials November 7th, 2017

Park Systems Announces the Grand Opening of the Park NanoScience Center at SUNY Polytechnic Institute November 3rd, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Moving at the Speed of Light: University of Arizona selected for high-impact, industrial demonstration of new integrated photonic cryogenic datalink for focal plane arrays: Program is major milestone for AIM Photonics August 10th, 2017

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Understanding brain functions using upconversion nanoparticles: Researchers can now send light deep into the brain to study neural activities February 14th, 2018

Announcements

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

European & Korean Project To Demo World’s First 5G Platform During Winter Games February 15th, 2018

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Rutgers-Led Innovation Could Spur Faster, Cheaper, Nano-Based Manufacturing: Scalable and cost-effective manufacturing of thin film devices February 14th, 2018

Joseph N. Pelton named 2017 Lifeboat Foundation Guardian Award Winner February 1st, 2018

Silk fibers could be high-tech ‘natural metamaterials’ January 31st, 2018

A simple new approach to plastic solar cells: Osaka University researchers intelligently design new highly efficient organic solar cells based on amorphous electronic materials with potential for easy printing January 28th, 2018

Nanobiotechnology

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Understanding brain functions using upconversion nanoparticles: Researchers can now send light deep into the brain to study neural activities February 14th, 2018

Alliances/Trade associations/Partnerships/Distributorships

New era in high field superconducting magnets – opening new frontiers in science, nanotechnology and materials discovery January 9th, 2018

Leti Field Trials Demonstrate New Multicarrier Waveform for Rural, Maritime Broadband Radio: Field Trial in Orkney Islands Used New Filtered Multicarrier Waveform at 700MHz Band with Flexible Bandwidth Usage (Fragmented and Continuous Spectrum) December 18th, 2017

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

JPK Instruments announce partnership with Swiss company, Cytosurge AG. The partnership makes Cytosurge’s FluidFM® technology available on the JPK NanoWizard® AFM platform December 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project